Venture investors and even some other biopharma giants appear much more optimistic about gene editing-based companies, given the year-over-year increases in total capital raised by many such startups . . .
Top 10 Companies Leveraging Gene Editing in 2019
While biopharma giants and VCs warm up to startups leading the field, wall street isn’t as enthusiastic
Source: liulolo/Getty Images